FDA Grants Orphan Drug Status for Pharmaxis Anti Fibrotic Drug for Myelofibrosis

14th Jul 20

Release Date: 14/07/2020 11:36am

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that the U.S. Food & Drug Administration (FDA) has granted orphan-drug designation for its oral pan LOX inhibitor PXS-5505 for the treatment of myelofibrosis.

Read full media release - pdf

Categories: News and Media